SCHEMBL13628306

SCHEMBL13628306

O=C(Nc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O)c1ccccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
HPGD P15428 3/20 0.41
CXCR5 P32302 1/20 0.37
MAPK8 P45983 1/20 0.37
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
USP2 O75604 2/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
NPY2R P49146 1/20 0.35
GALR3 O60755 1/20 0.34
NR2F2 P24468 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HIF1A Q16665 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628302 0.92 RAB9A (0.42) ALDH1A1KDM4EHPGDCXCR5MAPK8
SCHEMBL13628201 0.91 RAB9A (0.38) ALDH1A1HPGDCXCR5MAPK8RAB9A
SCHEMBL13628304 0.91 RAB9A (0.41) ALDH1A1HPGDCXCR5MAPK8RAB9A
SCHEMBL13628203 0.90 NPC1 (0.43) ALDH1A1KDM4EHPGDRAB9ANPC1
SCHEMBL13628195 0.89 RPS6KA2 (0.40) KDM4ECXCR5MAPK8RAB9ANPC1
SCHEMBL13628193 0.89 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDCXCR5MAPK8
SCHEMBL13628197 0.88 NPC1 (0.39) CXCR5MAPK8RAB9ANPC1POLB
SCHEMBL13628198 0.87 KMT2A (0.43) ALDH1A1KDM4EHPGDCXCR5MAPK8
SCHEMBL13628152 0.86 MAPK8 (0.39) ALDH1A1KDM4ECXCR5MAPK8RAB9A
SCHEMBL13628167 0.86 GRM1 (0.42) ALDH1A1RAB9ANPC1POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885KDM4E 2171/4885HPGD 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.